<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2021</study_start_year><data_sharing_plan>IPD Sharing (as of January 2021): No</data_sharing_plan><condition>Neoplasm Metastasis</condition><condition>Lung Metastases</condition><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><condition>Lung Neoplasms</condition><disease>Lung Metastases</disease><disease>Neoplasm Metastasis</disease><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><disease>Lung Neoplasms</disease><study_type>Observational</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2363556</full_dataset_link><location>South Korea</location><study_start_month>2</study_start_month><repository>ECRIN MDR</repository><study_status>Not yet recruiting</study_status></additional><is_claimable>false</is_claimable><name>CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy</name><description>The investigators will detect circulating tumor DNA in blood of patients with lung metastases from colorectal cancer using NGS technology and intend to use it for predicting the outcome of local treatment (surgery or radiation) and recurrence of lung metastases.</description><dates><creation>2021-02-15</creation></dates><accession>2363556</accession><cross_references><ClinicalTrials___gov>NCT04704960</ClinicalTrials___gov></cross_references></HashMap>